Figure 4.
Comparative analysis of immunotherapy markers between MTAP-loss and MTAP-intact tumors. Only statistically significant findings are shown and includes colorectal carcinoma (CRC), intrahepatic cholangiocarcinoma (IHCC), and pancreatic ductal adenocarcinoma (PDAC). (A) MSI analysis, (B) PD-L1 analysis, (C) mean tumor mutation burden, and (D) tumor mutation burden at commonly used cutoffs. *P ≤ .05; **P ≤ .01; ***P ≤ .001; ****P ≤ .0001. (-) is Negative, (+) is Positive.